Infliximab injection therapy outcomes in inflammatory bowel disease
Part of Digestive system clinical trials.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease or ulcerative colitis (not unclassified colitis)
- You've received at least one subcutaneous (under-the-skin) infliximab injection following the standard IV starting dose
- Your disease was active when infliximab started (abdominal pain or frequent stools for Crohn's; moderate symptoms for ulcerative colitis)
- You can commit to at least 3 months of follow-up (or shorter if the medication didn't work or caused side effects)
- You are not currently taking other biologic medications or small molecule therapies alongside infliximab
- You do not have a permanent stoma or prior total colon removal with pouch surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This study looks at whether giving infliximab as a shot under the skin, after initial IV doses, helps people with severe ulcerative colitis. It may help doctors understand if this easier way of taking the medicine works well over a year.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.